Alchemia Ltd Shares Rise 20% on Lung Cancer Trial Update
By Rebecca Evans -
2011-09-28T00:06:07Z
Alchemia Ltd. shares rose 20% in Sydney trading after the company said its HA-Irinotecan product showed promising results in its first two small cell lung cancer patients reporting substantial shinkage of their tumors after 10 days.
To contact the editor responsible for this story: Rebecca Evans at revans6@bloomberg.net
Rate this Page
Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.